Understanding Lung Cancer Growth and Drug Response in EGFR Mutations
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer
This project aims to discover the genetic changes that make EGFR-mutant lung cancers grow and become resistant to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11094783 on NIH RePORTER |
What this research studies
For patients with EGFR-mutant lung cancer, current treatments called TKIs can work well, but their effectiveness varies, and resistance often develops over time. This research uses advanced genetic tools, including CRISPR/Cas9 technology, in a specialized mouse model that closely mimics human lung cancer. By studying how different genetic changes, particularly in tumor suppressor genes, affect cancer growth and response to drugs, we hope to find new ways to overcome treatment resistance. This approach helps us understand why some tumors respond better than others and what causes them to stop responding.
Who could benefit from this research
Good fit: This foundational research focuses on understanding the biology of EGFR-mutant lung cancer, which could eventually benefit patients diagnosed with this specific type of lung cancer.
Not a fit: Patients with lung cancer types other than EGFR-mutant, or those without lung cancer, would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatment strategies or ways to predict which therapies will work best for patients with EGFR-mutant lung cancer, helping to overcome drug resistance.
How similar studies have performed: While the use of CRISPR/Cas9 in advanced mouse models is a cutting-edge approach, previous studies have shown the importance of understanding genetic interactions in cancer and the development of drug resistance.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Politi, Katerina Abigail — Yale University
- Study coordinator: Politi, Katerina Abigail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.